In 2010, Samuel R. Saks earned $765.61K in total compensation at Jazz Pharmaceuticals, including $496.88K salary and $267.30K bonus. Currently holds stock worth $947.16K. Led Jazz Pharmaceuticals as CEO for 3 years.
Compensation History
Annual executive compensation data for Samuel R. Saks, including salary, bonuses, and stock awards.
Year
2010
Total Compensation
$765.61K
Salary
$496.88K
Bonus
$267.30K
Other
$1.44K
Salary
$496.88KBoard Justification
The compensation philosophy aims to ensure competitive total compensation packages for executive officers, targeting the 50th percentile for cash compensation and 60th percentile for long-term incentives based on peer benchmarking.
Bonus
$267.30KBoard Justification
The bonus for 2010 was calculated based on the company's performance against key corporate objectives, with a target bonus of 60% of the applicable annual base salary.
Other Compensation
$1.44KBoard Justification
Represents group term life insurance premiums paid by the Company.
Restricted Stock
Board Justification
No stock was reported as vested in 2010 for the CEO.
Performance Metrics
The performance metrics included achieving budgeted net sales and cash EBITDA, refinancing existing debt, and obtaining FDA approval for a new drug.
Samuel R. Saks
Ex-CEO of Jazz Pharmaceuticals
Education
Not specified
Field of Expertise
Healthcare & Life Sciences - Pharmaceuticals
Sector of Economy
Healthcare
Born
January 1, 1963 - 62 years ago
CEO of Jazz Pharmaceuticals for
3 years 2 months (Jan 2008 - Mar 2011)
Previous Experience
Served as Chief Executive Officer of Jazz Pharmaceuticals, Inc. until March 2011
Other Jazz Pharmaceuticals CEOs
Holdings
Track Samuel R. Saks's stock holdings and portfolio value over time.
Insider Trading
Samuel R. Saks's recent stock transactions, purchases, and sales filed with the SEC.
No insider trades found for this CEO.
Rivals
Compare Samuel R. Saks with competitor CEOs and industry peers.